Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2022 Financial Results and Corporate Update

Rhea-AI Summary

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced a conference call on February 16, 2023, at 5:00 p.m. ET, to discuss its financial results for Q4 and the full year ending December 31, 2022. This call will provide insights into the company's performance in developing therapies for rare genetic diseases. Interested participants can access the live call via the company's website, and a replay will be available for one year. Ultragenyx focuses on novel therapies to meet the high unmet medical needs of patients with rare diseases.

NOVATO, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Thursday, February 16, 2023, at 5:00 p.m. ET to discuss its financial results and corporate update for the fourth quarter and the year ending December 31, 2022.

The live and replayed webcast of the call will be available through the company’s website at https://ir.ultragenyx.com/events-presentations. To participate in the live call, please register by clicking on the following link (registration link) and you will be provided with dial-in details. The replay of the call will be available for one year.

About Ultragenyx Pharmaceutical Inc.

Ultragenyx is a biopharmaceutical company committed to bringing novel therapies to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved medicines and treatment candidates aimed at addressing diseases with high unmet medical need and clear biology, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

Contacts
Ultragenyx Pharmaceutical, Inc.
Investors
Joshua Higa
415-475-6370
IR@ultragenyx.com

Media
Jeff Blake
415-612-7784
media@ultragenyx.com

FAQ

When is Ultragenyx's next conference call to discuss financial results?

Ultragenyx will host a conference call on February 16, 2023, at 5:00 p.m. ET.

What will be discussed in Ultragenyx's February conference call?

The call will discuss Ultragenyx's financial results for the fourth quarter and the year ending December 31, 2022.

How can I access the Ultragenyx conference call?

Participants can join the live call by registering on Ultragenyx's website, where a replay will also be available for one year.

What is Ultragenyx's focus as a biopharmaceutical company?

Ultragenyx is focused on developing novel therapies for serious rare and ultra-rare genetic diseases.